Trial · NCT03222609
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 | Navitoclax + Ruxolitinib (Cohort 1a) | 26.47 | 95% Confidence Interval 12.88 to 44.36 | percentage of participants | |
| Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 | Navitoclax + Ruxolitinib (Cohort 1b) | 21.98 | 95% Confidence Interval 13.97 to 31.88 | percentage of participants | |
| Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 | Navitoclax (Cohort 2) | 11.76 | 95% Confidence Interval 3.30 to 27.45 | percentage of participants | |
| Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 | Navitoclax + Ruxolitinib (Cohort 3) | 62.50 | 95% Confidence Interval 43.69 to 78.90 | percentage of participants | |
| Percentage of Participants Achieving ≥ 50% Reduction From Baseline in Total System Score (TSS) at Week 24 | Navitoclax + Ruxolitinib (Cohort 1a) | 20.59 | 95% Confidence Interval 8.70 to 37.90 | percentage of participants | |
| Percentage of Participants Achieving ≥ 50% Reduction From Baseline in Total System Score (TSS) at Week 24 | Navitoclax + Ruxolitinib (Cohort 1b) | 25.27 | 95% Confidence Interval 16.75 to 35.47 | percentage of participants | |
| Percentage of Participants Achieving ≥ 50% Reduction From Baseline in Total System Score (TSS) at Week 24 | Navitoclax (Cohort 2) | 8.82 | 95% Confidence Interval 1.86 to 23.68 | percentage of participants | |
| Percentage of Participants Achieving ≥ 50% Reduction From Baseline in Total System Score (TSS) at Week 24 | Navitoclax + Ruxolitinib (Cohort 3) | 34.38 | 95% Confidence Interval 18.57 to 53.19 | percentage of participants | |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1a) | Baseline transfusion independent with Baseline HGB <10 g/dL | 28.57 | 95% Confidence Interval 3.67 to 70.96 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1b) | Baseline transfusion independent with Baseline HGB <10 g/dL | 23.68 | 95% Confidence Interval 11.44 to 40.24 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax (Cohort 2) | Baseline transfusion independent with Baseline HGB <10 g/dL | 52.94 | 95% Confidence Interval 27.81 to 77.02 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 3) | Baseline transfusion independent with Baseline HGB <10 g/dL | 38.46 | 95% Confidence Interval 13.86 to 68.42 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1a) | Baseline transfusion dependent | 50.00 | 95% Confidence Interval 6.76 to 93.24 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1b) | Baseline transfusion dependent | 16.67 | 95% Confidence Interval 2.09 to 48.41 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax (Cohort 2) | Baseline transfusion dependent | 37.50 | 95% Confidence Interval 8.52 to 75.51 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 3) | Baseline transfusion dependent | 100 | 95% Confidence Interval 15.81 to 100.00 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1a) | Overall | 36.36 | 95% Confidence Interval 10.93 to 69.21 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 1b) | Overall | 22.00 | 95% Confidence Interval 11.53 to 35.96 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax (Cohort 2) | Overall | 48.00 | 95% Confidence Interval 27.80 to 68.69 | percentage of participants |
| Percentage of Participants Achieving Anemia Response | Navitoclax + Ruxolitinib (Cohort 3) | Overall | 46.67 | 95% Confidence Interval 21.27 to 73.41 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03222609/results